Taiwan’s Bora Pharmaceuticals Posts Second-Highest Monthly Revenue of NT$2.18 Billion in August; Sale-Leaseback Deal to Add Over NT$16 Million in Annual Cash Flow
Bora Pharmaceuticals reported August consolidated revenue of NT$2.18 billion, up 15% month-over-month and 59.22% year-over-year, marking its second-highest monthly figure on record, driven primarily by the shipment of CDMO orders deferred from July.